GAA and Glycogen storage disease due to acid maltase deficiency: Enzyme replacement therapy (ERT) currently is the only approved treatment for Pompe disease, administered as a bi-weekly intravenous infusion of recombinant human GAA (rhGAA; alglucosidase alfa, marketed as Myozyme and Lumizyme, Genzyme Corp., a Sanofi company, Cambridge, MA).